Astrazeneca (AZN) Finished Goods (2015 - 2025)

Astrazeneca's Finished Goods history runs 11 years deep, the most recent figure standing at $1.9 billion for Q4 2025.

• In Q4 2025, Finished Goods rose 26.76% year-over-year to $1.9 billion; the TTM figure through Dec 2025 stood at $1.9 billion (up 26.76% YoY), while the FY2025 annual figure was $1.9 billion, up 26.76% from the prior year.
• Finished Goods was $1.9 billion for Q4 2025 at Astrazeneca, up from $1.5 billion in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $2.0 billion in Q4 2021 to a low of $1.4 billion in Q4 2022.
• Historically, Finished Goods has averaged $1.7 billion across 5 years, with a median of $1.6 billion in 2023.
• The sharpest annual moves came in 2021 and 2022: Finished Goods surged 40.6% in 2021, then declined 29.77% in 2022.
• A 5-year view of Finished Goods shows it stood at $2.0 billion in 2021, then dropped by 29.77% to $1.4 billion in 2022, then grew by 10.97% to $1.6 billion in 2023, then slipped by 3.25% to $1.5 billion in 2024, then rose by 26.76% to $1.9 billion in 2025.
• The last three Finished Goods figures came in at $1.9 billion (Q4 2025), $1.5 billion (Q4 2024), and $1.6 billion (Q4 2023), per Business Quant data.